Innoviva (INVA) revenue breakdown
By product, Royalty Revenue is the largest at 58% of fiscal 2025 revenue; XACDURO grew fastest, 509% a year over 2 years.
Revenue by product
Fiscal years, as Innoviva reports them in its 10-K filings; fiscal 2025 total $411M.
| Products | 2016 | 2017 | 2020 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Royalty Revenue | $133M | $214M | $327M | $312M | $239M | $242M | $236M | 58% |
| XACDURO | — | — | — | — | $2M | $21M | $74M | 18% |
| GIAPREZA | — | — | — | $14M | $41M | $55M | $74M | 18% |
| XERAVA | — | — | — | $5M | $17M | $21M | $24M | 6% |
| License and other revenue | — | — | — | — | $11M | $19M | $3M | 1% |
| Revenue from collaborative arrangements | $885,000 | $3M | $10M | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for INVA.
Open INVA in InvestinglyQuestions
Where does Innoviva make its money?
In fiscal 2025, by product: Royalty Revenue $236M, XACDURO $74M, GIAPREZA $74M, XERAVA $24M, License and other revenue $3M.
From Innoviva's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.